New research from life sciences industry software provider Veeva Systems (NYSE: VEEV) finds that all respondents surveyed report the need to improve information exchange among study partners.
On average, they utilize at least three methods to share trial data and documents among sponsors, CROs, and sites, with email as the primary tool.
Majorities say the move to streamline information exchange is driven by the need to reduce manual processes, improve collaboration, and increase visibility and oversight during trials.
Nearly all sponsors and CROs say they also need to unify clinical applications for greater visibility and easier collaboration.
Many of the challenges in managing trials stem from siloed processes and systems that prevent a complete view of study progress and slow trial execution. Integration and reporting are the top two issues cited both are the direct result of clinical system silos.
Study start-up is one of the clinical areas with the most potential to improve trial efficiency and speed. All respondents report significant challenges with study start-up, likely due to the heavy reliance on manual processes since most use spreadsheets to manage this area.
Sponsors and CROs are increasingly adopting purpose-built study start-up applications to speed cycle times. Nearly one-quarter of respondents are now using newer, purpose-built study start-up applications.
Findings show that the majority cite faster study start-up times as the primary driver to improve study start-up processes.
Half of respondents say easier collaboration during study start-up is also an area of improvement, highlighting the importance of collaboration in driving clinical trial efficiency and speed.
Over the past several years, sponsors and CROs have steadily adopted function-specific applications to improve study execution.
The industry is modernizing its processes and systems in major clinical areas such as eTMF and are seeing positive impact.
Sponsors and CROs, however, report challenges in other areas such as CTMS because of the prevalence of legacy systems.
Nearly all respondents say they need to improve the use of CTMS in clinical operations. For most, better analytics and reporting and increased visibility are among the primary reasons.
Roughly half of sponsors and CROs also say easier collaboration is a top driver, underscoring the importance of streamlining communication and information sharing during execution.
The number of respondents using purpose-built eTMF applications has tripled since 2014.
At the same time, the use of general-purpose methods to manage TMF processes has decreased, indicating the continued move from TMFs that act as static repositories to store and archive documents upon completion to modern purpose-built eTMF applications that enable more 'active' trial management.
Those using purpose-built eTMF solutions report improved ability to maintain a constant state of inspection-readiness and visibility into TMF status.
The Veeva 2019 Unified Clinical Operations Survey examines the life sciences industry's progress toward a unified clinical environment by gathering the experiences and opinions of 461 clinical operations professionals from around the globe.
The annual research examines the drivers, barriers, and benefits of a unified clinical operating model and tracks the industry's progress in its move to unify clinical systems and processes and align stakeholders throughout study execution.
Veeva Systems is in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 750 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs.
Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering